Academic Journals Database
Disseminating quality controlled scientific knowledge

The efficacy, tolerance and safety of calciumlactogluconate in the treatment of osteopeniaand osteoporosis in the developmental age.Part I. Clinical and densitometric assessment --- Analiza skutecznosci, tolerancji i bezpieczenstwa leczenia laktoglukonianem wapnia osteopenii i osteoporozy w wieku rozwojowym. Czesc 1. Ocena kliniczna i densytometryczna

Author(s): Danuta Chlebna-Sokol | Elzbieta Jakubowska-Pietkiewicz | Agnieszka Rusinska, Agnieszka Kilianska | Izabela Michalus | Jolanta Frasunkiewicz | Katarzyna Kulinska-Szukalska | Beata Romanowska-Pietrasiak

Journal: Przegląd Pediatryczny
ISSN 0137-723X

Volume: 37;
Issue: 2;
Start page: 188;
Date: 2007;
Original page

Introduction: The aim of the study was clinical and densitometric evaluation of efficacy, tolerance and safety of treatment of osteopenia and osteoporosis during the developmental age with calcium lactogluconate. Material and methods: The study comprised 100 patients aged 5 to 19 years with low bone mineral density (BMD): in 40 cases osteoporosis and in 60 - osteopenia was diagnosed. The children were treated with calcium lactogluconate (Calcium 500D preparation) in diversified dose corresponding to diagnosis and lowering of BMD. The detailed clinical and densitometric evaluation (DXA and ultrasound of the heel) were carried out before and after 12 months of the therapy. Results: The applied treatment decreased clinical symptoms of skeletal-muscular disorders, only in 3 of patients the new bone fracture was present. No somatic development abnormalities were observed. Children usually tolerated the preparation well, and appearance of deposits in renal pelvis only in 2 patients (2%) points on safety of the treatment. In 90% of children stabilization or improvement of Z-score total body parameter was present; for Z-score spine - in 84%. The improvement of Z-score ultrasound of the heel parameters was found in more then 1/3 of studied population, simultaneously the number of children with incorrect values of those parameters was lower. The mean increase in absolute, both DXA and ultrasound parameters, was statistically significant. Conclusions: 1. Calcium lactogluconate has a positive influence on clinical symptoms, and bone mineral density assessed both by densitometric and ultrasound methods and on bone quality in children with osteoporosis and osteopenia. 2. Regular intake of the preparation within 12 months is well-tolerated and can be recognized as safe.
Why do you need a reservation system?      Affiliate Program